Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q3 FY21 results · Oct–Dec 2020

Sun Pharmaceutical Industries reported revenue from operations of ₹8,836.78 crore (up 8.4% from Q3 FY20) and net profit of ₹1,913.41 crore (up 87.7% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY21	Q3 FY20	YoY	Q2 FY21	QoQ
Revenue from operations	8,836.78	8,154.85	+8.4%	8,553.13	+3.3%
Other income	314.95	119.88	+162.7%	255.78	+23.1%
Total income	9,151.73	8,274.73	+10.6%	8,808.91	+3.9%
Profit before share of associates & JVs and tax	2,163.05	1,351.33	+60.1%	1,917.18	+12.8%
Share of profit/(loss) of associates & JVs	(4.70)	(4.33)		(5.62)
Net profit for the period	1,913.41	1,019.38	+87.7%	1,942.76	−1.5%
Attributable to shareholders of the company	1,852.48	913.52	+102.8%	1,812.79	+2.2%
EPS, basic (₹)	7.72	3.81	+102.6%	7.56	not comparable
Net margin (%)	21.7	12.5		22.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY21	Q3 FY20	YoY	Q2 FY21	QoQ
Revenue from operations	3,388.02	3,013.55	+12.4%	3,292.51	+2.9%
Other income	20.98	15.36	+36.6%	73.18	−71.3%
Total income	3,409.00	3,028.91	+12.5%	3,365.69	+1.3%
Profit before tax	548.40	478.01	+14.7%	701.88	−21.9%
Net profit for the period	555.55	468.76	+18.5%	724.81	−23.4%
EPS, basic (₹)	2.32	1.95	+19.0%	3.02	not comparable
Net margin (%)	16.4	15.6		22.0

Consolidated

Filed with BSE: 30 Jan 2021, 09:39 IST
Board meeting: 29 Jan 2021
Period: 01 Oct 2020 to 31 Dec 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jan 2021, 09:39 IST
Board meeting: 29 Jan 2021
Period: 01 Oct 2020 to 31 Dec 2020
Review status: Unaudited
Source: XBRL filing on BSE